We claim,

1. A non-acidic extract/fraction selected from Boswellia low polar gum resin extract fraction (BLPRE), Boswellia volatile oil fraction (BVOIL) and Boswellia oil fraction (BOIL) derived from the gum resin of Boswellia species for improving mental condition/brain health;enhancing brain functions such as cognition, memory, learning, communication; for treating impaired memory, and for preventing, control or treating memory and cognition related disorders/diseases.

2. A composition comprising atleast one Boswellia derived non-acidic extract/fraction selected from Boswellia low polar gum resin extract fraction (BLPRE), Boswellia volatile oil fraction (BVOIL) and non-acidic Boswellia oil fraction (BOIL) in combination with at least one component selected from biological agents, phytochemicals, vitamins, amino acids, minerals; pharmaceutically or dietetically acceptable excipients, vehicles, carriers and diluents or mixtures thereof for improving mental condition/brain health; enhancing brain functions such as cognition, memory, learning, communication; for treating impaired memory, and for preventing, control or treating memory and cognition related disorders/diseases.

3. The Boswellia derived non-acidic extract/fractions as claimed in claims 1 and 2, wherein the Boswellia species can be selected from Boswellia serrata, Boswellia carterii, Boswellia papyrifera, Boswellia ameero, Boswellia bullata, Boswellia dalzielii, Boswellia dioscorides, Boswellia elongata, Boswellia frereana, Boswellia nana, Boswellia neglecta, Boswellia ogadensis, Boswellia pirottae, Boswellia popoviana, Boswellia rivae, Boswellia sacra and Boswellia socotrana.

4. The Boswellia derived non-acidic extract/fraction or their composition(s) according to claims 1 and 2, to prevent, control and treat memory and cognition related disorders/diseases, which include ~~but not limited to~~ senile dementia, multi- infarct dementia, dyslexia, aphasia, organic brain syndrome, myasthenia gravis, vascular dementia, mild cognitive impairment (MCI), Attention-deficient Hyperactivity Disorder (ADHD), Lewy body dementia, Wemicke-Korsakoff- syndrome, Alzheimer's, Parkinson's disease, hypoxia, anoxia, cerebrovascular insufficiency, epilepsy, myoclonus and hypocholinergic dysfunctions, memory impairment disorders and neurodegenerative disorders.

5. The Boswellia derived non-acidic extract/fraction or their composition(s) according to claims 1 and 2, for improving mental condition/brain health by slowing down memory deterioration, functional loss, by inhibiting beta-amyloid plaque deposition, by controlling blood pressure and blood circulation in the brain.

6. The composition according to claim 2, wherein the biological agent(s) used for making the composition comprise one or more agent(s) selected from dietary supplements, herbal ingredients, nutraceuticals, functional ingredients, functional foods and nootropic agents.

7. The compositions according to claim 2, wherein the biologicalagent(s) is selected from natural antioxidants, neuroprotecting agents, anti-inflammatory agents and immune modulators.

8. The biological agent(s) used for making the compositions as claimed in claim 6, where in the herbal ingredients are selected from extracts, fractions, standardized extracts/fractions or pure phytochemicals derived from plants or mixtures there-of.

9. The biological agent used for making the compositions as claimed in claim 2 is a Boswellia serrata derived component selected from the extract(s) or fraction(s) containing boswellic acids, extracts or fractions selectively enriched with one or more boswellic acids, pure boswellic acid compounds or mixtures thereof.

10. The biological agent used for making the compositions as claimed in claim 2 is a Boswellia serrata extract standardized to 30 - 100 % total boswellic acids by titrimetric method of analysis or 20 - 100% total boswellic acids by HPLC method of analysis.

11. The biologically active ingredientused for making the compositions as claimed in claim 2 is a Curcuma longa derived component selected from the extract(s), fraction(s) extracts or fractions selectively enriched with one or more curcuminoids, pure curcuminoid compounds or mixtures thereof.

12. The Nootropic agents according to claim 6, selected from extract(s), fraction(s) or phytochemicals derived from Bacopa monnieri, Withania somnifera, Emblica officinalis, Centella asiatica; extract or fraction enriched in one or more phytochemicals selected from including ~~but not limited to~~ Bacoside A3, Bacopaside II, Jujubogenin isomer of bacopasaponin C, Bacopasaponin C, Bacopaside I, Bacosine, Apigenin, Luteolin and Sitosterol-D-glucoside, curcumin, demethoxycurcumin, bisdemethoxycurcumin, monodemethylcurcumin, bisdemethylcurcumin, tetrahydrocurcumin, tetrahydrodemethoxycurcumin, tetrahydrobisdemethoxycurcumin and ar-turmerone, carnosic acid, rosmarinic acid, camphor, caffeic acid, ursolic acid, betulinic acid, rosmaridiphenol, rosmanol and their salts thereof.

13. The composition comprising atleast one Boswellia derived non-acidic extract/fraction as claimed in claim 2, wherein said pharmaceutically or dietetically acceptable excipients, vehicles, diluents and carriers comprises surfactants, binders, disintegrators, lubricants, preservatives, stabilizers, buffers and suspensions.

14. The Boswellia derived non-acidic extract/fraction or their composition(s) according to claims 1 and 2,wherein said extract/fraction or their composition(s) is formulated as oral agents such as tablets, soft capsule, hard capsule, soft gel capsules, pills, granules, powders, emulsions, suspensions, syrups, pellets, food, beverages, concentrated shots, drops and the like; parenteral agents such as injections, intravenous drip and the like;

suppositories; transdermal agents such as patches, topical creams and gel; ophthalmic agents and nasal agents.

15. The Boswellia derived non-acidic extract/fraction or their composition(s) according to claims 1 and 2, wherein said extract/fraction or their composition(s) is delivered in the form of controlled release dosage forms by using techniques including nanotechnology, microencapsulation, colloidal carrier systems and other drug delivery systems.

16. The Boswellia derived non-acidic extract/fraction or their composition(s) according to claims 1 and 2,wherein said extract/fraction or their composition(s) is formulated into or added to existing or new food and beverage form(s) as a healthy food for subject or warm blooded animal.

17. ~~A method of improving brain health and brain functions such as cognition, memory, learning, communication or treating impaired memory in a subject or warm blooded animal in need thereof, wherein the method comprises supplementing the said subject or warm blooded animal with an effective dose of Boswellia derived non-acidic extract/fraction or their composition(s) according to claims 1 and 2~~Use of an effective dose of Boswellia derived non-acidic extract/fraction or their composition(s) according to claims 1 and 2 in the preparation of a medicament for improving brain health and brain functions such as cognition, memory, learning, communication or treating impaired memory.

18. ~~A method of preventing, control or treating memory and cognition related disorders/diseases in a subject or warm blooded animal in need thereof, wherein the method comprises supplementing the said subject or warm blooded animal with an effective dose of Boswellia derived non-acidic extract/fraction or their composition(s) according to claims 1 and 2.~~ Use of an effective dose of Boswellia derived non-acidic extract/fraction or their composition(s) according to claims 1 and 2 in the preparation of a medicament for preventing, control or treating memory and cognition related disorders/diseases.

19. ~~The method of preventing, control or treating memory and cognition related disorders/diseases as claimed in claim 18, wherein memory and cognition related disorders/diseases include but not limited to senile dementia, multi-infarct dementia, dyslexia, aphasia, organic brain syndrome, myasthenia gravis, vascular dementia, mild cognitive impairment (MCI), Attention-deficient Hyperactivity Disorder (ADHD), Lewy body dementia, Wemicke-Korsakoff-syndrome, Alzheimer's, Parkinson's disease, hypoxia, anoxia, cerebrovascular insufficiency, epilepsy, myoclonus and hypocholinergic dysfunctions, memory impairment disorders and neurodegenerative disorders.~~ The use as claimed in claim 18, wherein the memory and cognition related disorders/diseases include senile dementia, multi-infarct dementia, dyslexia, aphasia, organic brain syndrome, myasthenia gravis, vascular dementia, mild

cognitive impairment (MCI), Attention-deficient Hyperactivity Disorder (ADHD), Lewy body dementia, Wemicke-Korsakoff-syndrome, Alzheimer's, Parkinson's disease, hypoxia, anoxia, cerebrovascular insufficiency, epilepsy, myoclonus and hypocholinergic dysfunctions, memory impairment disorders and neurodegenerative disorders.